Mer­ck-part­nered an­ti­body mak­er read­ies $300M IPO as HKEX picks up pace

Three weeks af­ter In­no­Care launched its IPO in­to the wel­com­ing em­brace of HKEX in­vestors, Ake­so­bio is look­ing to one-up the com­pa­ny with its own $300 mil­lion (HKD$2.34 bil­lion) raise.

Part­nered with Mer­ck, Ake­so­bio’s pitch cen­ters around a suite of in-house tech­nolo­gies that it says gen­er­ate su­pe­ri­or an­ti­bod­ies against known tar­gets such as PD-1, CT­LA-4, IL-12 and IL-23. Hav­ing kicked off pre-mar­ket­ing on Mon­day, it ex­pects to make a pub­lic de­but this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER